Brokerages Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $26.33

Alto Neuroscience, Inc. (NYSE:ANRO) has earned an average recommendation of “Moderate Buy” from the eight research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $26.3333.

A number of equities analysts have issued reports on ANRO shares. Wall Street Zen upgraded shares of Alto Neuroscience from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Robert W. Baird raised their price objective on shares of Alto Neuroscience from $16.00 to $22.00 and gave the stock an “outperform” rating in a research note on Thursday, November 13th. HC Wainwright upped their target price on Alto Neuroscience from $10.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 24th. Chardan Capital increased their target price on Alto Neuroscience from $15.00 to $30.00 and gave the company a “buy” rating in a report on Monday, January 5th. Finally, Jefferies Financial Group boosted their price target on Alto Neuroscience from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC boosted its stake in shares of Alto Neuroscience by 0.7% during the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock worth $6,577,000 after purchasing an additional 12,000 shares during the last quarter. Susquehanna International Group LLP raised its position in shares of Alto Neuroscience by 154.9% in the third quarter. Susquehanna International Group LLP now owns 155,676 shares of the company’s stock valued at $626,000 after buying an additional 94,613 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Alto Neuroscience by 4.3% during the third quarter. Millennium Management LLC now owns 315,758 shares of the company’s stock valued at $1,269,000 after buying an additional 12,896 shares during the period. Two Sigma Investments LP boosted its position in Alto Neuroscience by 160.6% during the third quarter. Two Sigma Investments LP now owns 116,579 shares of the company’s stock worth $469,000 after acquiring an additional 71,844 shares during the last quarter. Finally, Bridgeway Capital Management LLC boosted its position in Alto Neuroscience by 43.5% during the third quarter. Bridgeway Capital Management LLC now owns 77,653 shares of the company’s stock worth $312,000 after acquiring an additional 23,553 shares during the last quarter.

Alto Neuroscience Stock Up 1.1%

ANRO opened at $17.21 on Thursday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 15.42 and a current ratio of 15.42. The company has a market cap of $534.74 million, a price-to-earnings ratio of -7.52 and a beta of 2.78. Alto Neuroscience has a one year low of $1.60 and a one year high of $20.91. The business’s fifty day moving average is $15.66 and its two-hundred day moving average is $8.78.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.14. Analysts anticipate that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.